NervGen Pharma Corp

05/28/2025

NervGen’s clinical trial for its lead drug candidate, NVG-291, has a unique design where we study connectivity using electrophysiology in partnership with Shirley Ryan AbilityLab.

Watch to learn more: https://bit.ly/NervGenBreakingNewGround

05/23/2025

Did you know that spinal cord injury (SCI) affects over 300,000 people in the U.S. and there are currently no approved drugs to enable sustained functional recovery?

We are working to change that at NervGen. Our lead drug candidate, NVG-291, is a first-in-class experimental drug that works by helping promote natural repair processes to improve the connections disrupted by a spinal cord injury.

Learn more: https://bit.ly/NervGenSCIPipeline

05/16/2025

Did you know that there are approximately 18,000 new spinal cord injury (SCI) cases each year in the U.S.?

At NervGen, we are dedicated to developing innovative treatments to enable nervous system repair in settings of traumatic injury and disease potentially helping those living with .

Learn more: https://bit.ly/NervGenBreakingNewGround

01/10/2025

We are deeply saddened by the passing of Dr. Jerry Silver, whose groundbreaking work laid the foundation for our mission to help individuals with spinal cord injury.

Read our full statement honoring his legacy: https://nervgen.com/wp-content/uploads/2025/01/NervGen-Honors-Renowned-Scientist-Dr.-Jerry-Silver.pdf?utm_campaign=organic&utm_medium=social&utm_source=facebook

10/28/2024

Our Phase 1b/2a clinical trial with NVG-291 in is enrolling subjects. Visit https://connectscistudy.com to learn more about the study, including eligibility requirements.

10/17/2024

Dr. Monica Perez of Shirley Ryan AbilityLab was featured on the Empowered Patient Podcast, hosted by Karen Jagoda.

Dr. Perez provided an overview of the current standard of care for spinal cord injuries, why NVG-291, our lead drug candidate, has the potential to enable spinal cord repair, and our CONNECT SCI Study for .

Learn more about the spinal cord injury study and its eligibility requirements at https://www.connectscistudy.com/

Listen to the episode:
https://empoweredpatientradio.com/regeneration-in-the-cns-to-recover-function-from-spinal-cord-injury-with-dr-monica-perez-shirley-ryan-abilitylab-transcript

10/10/2024

- Dr. Monica Perez from Shirley Ryan AbilityLab spoke with Dina Bair from WGN-TV about our CONNECT SCI Study, which is exploring the potential of NVG-291 as a treatment candidate.

“We hope that neurons grow and sprout to other connections so the connectivity will be stronger, therefore patients will be able to complete movement or restore movement.” – Dr. Monica Perez.

Learn more about eligibility requirements and enrollment: https://www.connectscistudy.com/

Watch the video: https://wgntv.com/video/chicago-researchers-study-promising-drug-for-spinal-cord-injuries/9822270/

10/09/2024

- A TV segment on NBC News featured our CONNECT SCI Study with Shirley Ryan AbilityLab.

The discussion highlighted the importance of our NVG-291 research, as well as the impact of a potential new treatment for people living with spinal cord injury.

Learn more about the spinal cord injury study and its eligibility requirements at https://www.connectscistudy.com/

View NBC Chicago's segment
https://www.nbcchicago.com/top-videos-home/study-determining-whether-investigational-drug-can-aid-those-with-spinal-cord-injuries-underway/3458314/

09/05/2024

Today is World Spinal Cord Injury Day, first designated by The International Spinal Cord Society - ISCoS in 2016. Every year, an estimated 500,000 individuals suffer from a new spinal cord injury worldwide.

At NervGen, we’re dedicated to developing innovative treatments to enable the nervous system to repair itself. Our lead drug candidate, NVG-291, is currently in a clinical trial in our lead indication, spinal cord injury.

September is designated as Spinal Cord Injury Awareness Month.

Learn more about World SCI Day: https://www.iscos.org.uk/page/SciDay

09/03/2024

A spinal cord injury (SCI) occurs whenever there is damage to any part of the spinal cord, which can cause changes in feeling, movement, strength, and body functions below the site of injury.

Visit the CONNECT SCI Study website to learn more about SCI and find out more about eligibility requirements and how to enroll in our study. https://www.connectscistudy.com/

09/02/2024

Our CONNECT SCI Study examines the safety and effectiveness of an investigational treatment, NVG-291, that has the potential to repair nervous system damage.

The study is currently enrolling people living with to participate at a leading rehabilitation hospital in Chicago.

Visit the CONNECT SCI Study website to learn more about eligibility requirements and how to enroll. https://www.connectscistudy.com/

07/08/2024

Dr. Monica Perez from Shirley Ryan AbilityLab recently spoke with WGN TV about our CONNECT SCI Study.



Read more about what Dr. Perez had to say in the article below and learn more about the spinal cord injury study and its eligibility requirements at https://www.connectscistudy.com.

Chicago researchers are studying the novel drug NVG291, which targets growth inhibitors in the central nervous system, in a first-of-its-kind study for patients with spinal cord injuries, in the ho…